Fast. Painless. Safe. AI-Enabled.
Cloud-Based SaaS Business Model.
Breast cancer is the most common cancer in women worldwide and the leading cancer killer of women globally. Early detection has had a profound impact on breast cancer mortality. Improved screening, diagnosis, and treatment have resulted in a 40% reduction in mortality over the past two decades in the US. Nevertheless, every year over 45,000 women in the US and nearly 700,000 worldwide die from breast cancer.
Currently, the diagnosis of breast cancer requires a multi-step, invasive process including anxiety-inducing, often painful interventional procedures which require tissue sample acquisition for definitive diagnosis. Additionally, there is frequently a long waiting time until the sample has been interpreted by a pathologist.
Compelling data demonstrates that the field of Bio-crystallography has developed to a point where it may be the fundamental change needed to allow for the interrogation of the extracellular matrix at a molecular level, resulting in the definitive, non-invasive diagnosis of breast cancer. This painless, and cost-effective approach will not only improve the ability to reliably detect breast cancer at a single visit, but will be a critical component of leveling healthcare disparities in the US and globally.
